Clock in radiation oncology clinics: cost-free modality to alleviate treatment-related toxicity

References

• Siegel RL, Miller KD, Jemal A. 2020. Cancer statistics, 2020. CA Cancer J Clin. 70(1):7–30. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Berkey FJ. Managing the adverse effects of radiation therapy. Am Fam Physician. 2010;82(4):381–394.
   PubMed Web of Science ®Google Scholar
• Rubin NH. Influence of the circadian rhythm in cell division on radiation-induced mitotic delay in vivo. Radiat Res. 1982;89(1):65–76. doi:10.2307/3575685.
   PubMed Web of Science ®Google Scholar
• Ali YF, Cucinotta FA, Ning-Ang L, Zhou G. 2020. Cancer risk of low dose ionizing radiation. Front Phys. 8:234. doi:10.3389/fphy.2020.00234.
   Web of Science ®Google Scholar
• Gupta D, Shukla P, Munshi A, Aggarwal JP. 2012. Cardioprotective radiotherapy: the circadian way. Med Hypotheses. 78(3):353–355. doi:10.1016/j.mehy.2011.12.009.
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. 2006. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 22(3):375–382. doi:10.1016/j.molcel.2006.03.038.
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C. 2002. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo [published correction appears in Cell 2002 Dec 27;111(7):1055]. Cell. 111(1):41–50. doi:10.1016/s0092-8674(02)00961-3.
   PubMed Web of Science ®Google Scholar
• Scheiermann C, Kunisaki Y, Frenette PS. 2013. Circadian control of the immune system. Nat Rev Immunol. 13(3):190–198. doi:10.1038/nri3386.
   PubMed Web of Science ®Google Scholar
• Xiong H, Yang Y, Yang K, Zhao D, Tang H, Ran X. 2018. Loss of the clock gene PER2 is associated with cancer development and altered expression of important tumor-related genes in oral cancer. Int J Oncol. 52(1):279–287. doi:10.3892/ijo.2017.4180.
   PubMed Web of Science ®Google Scholar
• Ezzat A, Raja MA, Berry J, Zwaan F, Rahal M, El-Warith A. 1997. A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol. 8(7):663–667. doi:10.1023/a:1008228121390.
   PubMed Web of Science ®Google Scholar
• Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. 2014. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 111(45):16219–16224. doi:10.1073/pnas.1408886111.
   PubMed Web of Science ®Google Scholar
• Li J, Chen R, Ji M, Zou SL, Zhu LN. 2015. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 76(3):651–655. doi:10.1007/s00280-015-2804-x.
   PubMed Web of Science ®Google Scholar
• Zhang PX, Jin F, Li ZL, Wu WL, Li YY, Long JH, Chen GY, Chen XX, Gan JY, Gong XY, et al. 2018. A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy. Chronobiol Int. 35(2):240–248. doi:10.1080/07420528.2017.1397684.
   PubMed Web of Science ®Google Scholar
• Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Donald Harvey R, Paulos CM, et al. 2021. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 22(12):1777–1786. doi:10.1016/S1470-2045(21)00546-5.
   PubMedGoogle Scholar
• Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O’Quigley JM, Rich T. 2011. Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? Cancer. 117(2):414–420. doi:10.1002/cncr.25423.
   PubMed Web of Science ®Google Scholar
• Soták M, Sumová A, Pácha J. 2014. Cross-talk between the circadian clock and the cell cycle in cancer. Ann Med. 46(4):221–232. doi:10.3109/07853890.2014.892296.
   PubMed Web of Science ®Google Scholar
• Ikegami K, Refetoff S, Van Cauter E, Yoshimura T. 2019. Interconnection between circadian clocks and thyroid function. Nat Rev Endocrinol. 15(10):590–600. doi:10.1038/s41574-019-0237-z.
   PubMed Web of Science ®Google Scholar
• Westgate EJ, Cheng Y, Reilly DF, Price TS, Walisser JA, Bradfield CA, FitzGerald GA. 2008. Genetic components of the circadian clock regulate thrombogenesis in vivo. Circulation. 117(16):2087–2095. doi:10.1161/CIRCULATIONAHA.107.739227.
   PubMed Web of Science ®Google Scholar
• Kumar S, Chen D, Jang C, Nall A, Zheng X, Sehgal A. 2014. An ecdysone-responsive nuclear receptor regulates circadian rhythms in Drosophila. Nat Commun. 5(1):5697. doi:10.1038/ncomms6697.
   PubMedGoogle Scholar
• Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. 2010. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 5(6):e10995. doi:10.1371/journal.pone.0010995.
   PubMed Web of Science ®Google Scholar
• Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbara L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. 2016. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 24(2):324–331. doi:10.1016/j.cmet.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Knutsson A, Alfredsson L, Karlsson B, Åkerstedt T, Fransson EI, Westerholm P, Westerlund H. 2013. Breast cancer among shift workers: results of the WOLF longitudinal cohort study. Scand J Work Environ Health. 39(2):170–177. doi:10.5271/sjweh.3323.
   PubMed Web of Science ®Google Scholar
• Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA. 2003. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 95(11):825–828. doi:10.1093/jnci/95.11.825.
   PubMedGoogle Scholar
• Viswanathan AN, Hankinson SE, Schernhammer ES. 2007. Night shift work and the risk of endometrial cancer. Cancer Res. 67(21):10618–10622. doi:10.1158/0008-5472.CAN-07-2485.
   PubMed Web of Science ®Google Scholar
• Parent MÉ, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. 2012. Night work and the risk of cancer among men. Am J Epidemiol. 176(9):751–759. doi:10.1093/aje/kws318.
   PubMed Web of Science ®Google Scholar
• Blakeman V, Williams JL, Meng QJ, Streuli CH. 2016. Circadian clocks and breast cancer. Breast Cancer Research. 18(1):1–9. doi:10.1186/s13058-016-0743-z.
   PubMedGoogle Scholar
• Anjum B, Singh B, Verma R, Singh N, A Mahdi R, K Singh A, De Meester R, Wilczynska F, Takahashi A, Dharwadkar T, et al. 2012. Associations of circadian disruption of sleep and nutritional factors with risk of cancer. Open Nutraceuticals J. 5(1):124–135. doi:10.2174/1876396001205010124.
   Google Scholar
• Shafi AA, Knudsen KE. 2019. Cancer and the circadian clock. Cancer Res. 79(15):3806–3814. doi:10.1158/0008-5472.CAN-19-0566.
   PubMed Web of Science ®Google Scholar
• Roden LC, Rudner T, Rae D. 2017. Impact of chronotype on athletic performance: current perspectives. Chronophysiol Ther. 7:1–6. doi:10.2147/CPT.S99804.
   Google Scholar
• Archer SN, Robilliard DL, Skene DJ, Smits M, Williams A, Arendt J, von Schantz M. 2003. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 26(4):413–415. doi:10.1093/sleep/26.4.413.
   PubMed Web of Science ®Google Scholar
• Roemeling RV, Olshefski R, Langevin T, Berestka J, Reusch JJ, Reusch JE, Lakatua D, Wick MR, Hrushesky WJ. 1986. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 3(1):55–64. doi:10.3109/07420528609083160.
   PubMedGoogle Scholar
• Hrushesky WJ, Roemeling RV, Wood PA, Langevin TR, Lange P, Fraley E. High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer. Cancer Treat Rep. 1987;71(10):915–919. PMID: 3652055.
   PubMedGoogle Scholar
• Lévi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, et al. 1994. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 86(21):1608–1617. doi:10.1093/jnci/86.21.1608.
   PubMed Web of Science ®Google Scholar
• Focan C, Denis B, Kreutz F, Focan-Henrard D, Levi F. Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infus Chemother. 1995;5(3 Suppl 1):148–152. PMID: 8528976.
   PubMedGoogle Scholar
• Miglietta L, Bruzzone M, Ghione G, Pepe A, Marenghi C, Ragni N, Boccardo F. Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. Tumori. 2002;88(3):204–208. PMID: 12195758. doi:10.1177/030089160208800305.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karaboué A, Giacchetti S, Bouchahda M, Adam R, Garufi C, et al. 2020. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: randomized multicenter EORTC 05011 trial. Cancer Med. 9(12):4148–4159. doi:10.1002/cam4.3056.
   PubMed Web of Science ®Google Scholar
• Maria OM, Eliopoulos N, Muanza T. 2017. Radiation-induced oral mucositis. Front Oncol. 7:89. doi:10.3389/fonc.2017.00089.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Oster G, Hagiwara M, Sonis S. 2006. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 106(2):329–336. doi:10.1002/cncr.21622.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Sonis ST, Peterson DE. 2008. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 52(1):61–viii. doi:10.1016/j.cden.2007.10.002.
   PubMedGoogle Scholar
• Jiang D, Mierzwa ML, Huth B, Xie C, Barrett WL, Redmond KP, Forster N. 2015. Does time of daily treatment matter in radiation therapy for head and neck cancer? Int J Radiat Oncol Biol Phys. 93(3):E348. doi:10.1016/j.ijrobp.2015.07.1434.
   Google Scholar
• Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, et al. 2009. National cancer institute of Canada clinical trials group (HN3). Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the national cancer institute of Canada clinical trials group (HN3). Int J Radiat Oncol Biol Phys. 73(1):166–172. doi:10.1016/j.ijrobp.2008.07.009.
   PubMed Web of Science ®Google Scholar
• Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S, Pant MC, Verma NS. 2009. Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. Int J Radiat Biol. 85(6):504–509. doi:10.1080/09553000902883802.
   PubMed Web of Science ®Google Scholar
• Gu F, Farrugia MK, Duncan WD, Feng Y, Hutson AD, Schlecht NF, Repasky EA, Antoch MP, Miller A, Platek A, et al. 2020. Daily time of radiation treatment is associated with subsequent oral mucositis severity during radiotherapy in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 29(5):949–955. doi:10.1158/1055-9965.EPI-19-0961.
   PubMed Web of Science ®Google Scholar
• Brolese EK, Cihoric N, Bojaxhiu B, Sermaxhaj B, Schanne DH, Mathier E, Lippmann J, Shelan M, Eller Y, Aebersold DM, et al. 2021. The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden. Radiother Oncol. 158:162–166. doi:10.1016/j.radonc.2021.02.039.
   PubMed Web of Science ®Google Scholar
• Chan S, Rowbottom L, McDonald R, Bjarnason GA, Tsao M, Danjoux C, Barnes E, Popovic M, Lam H, DeAngelis C, et al. 2017. Does the time of radiotherapy affect treatment Outcomes? A review of the literature. Clin Oncol (R Coll Radiol). 29(4):231–238. doi:10.1016/j.clon.2016.12.005.
   PubMed Web of Science ®Google Scholar
• Shukla P, Gupta D, Bisht SS, Pant MC, Bhatt ML, Gupta R, Srivastava K, Gupta S, Dhawan A, Mishra D, et al. 2010. Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma. Cancer. 116(8):2031–2035. doi:10.1002/cncr.24867.
   PubMed Web of Science ®Google Scholar
• Chang L, Li L, Li W, Jiang M, Jv Y, Wang L, Hou Y, Long Q, Yu S. 2016. Research on radiotherapy at different times of the day for inoperable cervical cancer. Int J Clin Pharmacol Ther. 54(11):856–864. doi:10.5414/CP202654.
   PubMed Web of Science ®Google Scholar
• Hsu FM, Hou WH, Huang CY, Wang CC, Tsai CL, Tsai YC, Yu HJ, Pu YS, Cheng JC. 2016. Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiol Int. 33(2):210–219. doi:10.3109/07420528.2015.1130049.
   PubMed Web of Science ®Google Scholar
• Negoro H, Iizumi T, Mori Y, Matsumoto Y, Chihara I, Hoshi A, Sakurai H, Nishiyama H, Ishikawa H. Chronoradiation therapy for prostate cancer: morning proton beam therapy ameliorates worsening lower urinary tract symptoms. J Clin Med. 2020;9(7):2263. Published 2020 Jul 16. doi:10.3390/jcm9072263.
   PubMed Web of Science ®Google Scholar
• Noh JM, Choi DH, Park H, Huh SJ, Park W, Seol SW, Jeong BK, Nam SJ, Lee JE, Kil WH. 2014. Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. J Radiat Res. 55(3):553–558. doi:10.1093/jrr/rrt141.
   PubMed Web of Science ®Google Scholar
• Ishaq O, Valdimarsdottir H, Cooper BT, Modrek A, Redd W, Formenti SC. 2015. Effect of treatment time of day on radiation fatigue and toxicity in early-stage breast cancer patients after breast conserving surgery. Int J Radiat Oncol Biol Phys. 93(3):E54. doi:10.1016/j.ijrobp.2015.07.679.
   PubMedGoogle Scholar
• LaRiviere MJ, Chao HH, Doucette A, Kegelman TP, Taunk NK, Freedman GM, Vapiwala N. 2020. Factors associated with fatigue in patients with breast cancer undergoing external beam radiation therapy. Pract Radiat Oncol. 10(6):409–422. doi:10.1016/j.prro.2020.05.011.
   PubMed Web of Science ®Google Scholar
• Hasan S, Renz P, Packard M, Horrigan S, Gresswell S, Kirichenko AV. 2019. Effect of daily and every other day stereotactic body radiation therapy schedules on treatment-related fatigue in patients with hepatocellular Carcinoma. Pract Radiat Oncol. 9(1):e38–e45. doi:10.1016/j.prro.2018.06.005.
   PubMed Web of Science ®Google Scholar
• Johnson K, Chang-Claude J, Critchley AM, Kyriacou C, Lavers S, Rattay T, Seibold P, Webb A, West C, Symonds RP, et al. 2019. REQUITE consortium. genetic variants predict optimal timing of radiotherapy to reduce side-effects in breast cancer patients. Clin Oncol (R Coll Radiol). 31(1):9–16. doi:10.1016/j.clon.2018.10.001.
   PubMed Web of Science ®Google Scholar
• Sapienza LG, Nasra K, Berry R, Danesh L, Little T, Abu-Isa E. 2021. Clinical effects of morning and afternoon radiotherapy on high-grade gliomas. Chronobiol Int. 38(5):732–741. doi:10.1080/07420528.2021.1880426.
   PubMed Web of Science ®Google Scholar
• Elicin O, Koller Brolese E, Bojaxhiu B, Sermaxhaj B, Schanne DH, Mathier E, Lippmann J, Shelan M, Eller Y, Aebersold DM, et al. 2021. The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer. Radiother Oncol. 158:293–299. doi:10.1016/j.radonc.2021.04.004.
   PubMed Web of Science ®Google Scholar
• Robsahm TE, Tretli S, Dahlback A, Moan J. 2004. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control. 15(2):149–158. doi:10.1023/B:CACO.0000019494.34403.09.
   PubMed Web of Science ®Google Scholar
• Roychoudhuri R, Robinson D, Coupland V, Holmberg L, Møller H. 2009. Season of cancer diagnosis exerts distinct effects upon short- and long-term survival. Int J Cancer. 124(10):2436–2441. doi:10.1002/ijc.24213.
   PubMed Web of Science ®Google Scholar
• Kabolizadeh P, Wegner R, Bernard M, Heron D, Mintz A, Burton S. 2011. The effect of treatment time on outcome in non-small cell lung cancer brain metastases treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 81(2):S301. doi:10.1016/j.ijrobp.2011.06.1784.
   Google Scholar
• Badiyan SN, Ferraro DJ, Yaddanapudi S, Drzymala RE, Lee AY, Simpson JR, DeWees T, Rich KM, Robinson CG. 2012. Ep-1293 impact of time of day of gamma knife radiosurgery on survival for non-small cell lung cancer brain metastases. Radiotherapy and Oncology. 103(103):S491–2. doi:10.1016/S0167-8140(12)71626-2.
   Google Scholar
• Badiyan SN, Ferraro DJ, Yaddanapudi S, Drzymala RE, Lee AY, Silver SA, Dyk P, DeWees T, Simpson JR, Rich KM, et al. 2013. Impact of time of day on outcomes after stereotactic radiosurgery for non-small cell lung cancer brain metastases. Cancer. 119(19):3563–3569. doi:10.1002/cncr.28237.
   PubMed Web of Science ®Google Scholar
• Chan S, Rowbottom L, McDonald R, Zhang L, Bjarnason GA, Tsao M, Danjoux C, Barnes E, Lam H, Popovic M, et al. 2016. Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases? Ann Palliat Med. 5(4):267–279. doi:10.21037/apm.2016.09.05.
   PubMed Web of Science ®Google Scholar
• Chan S, Zhang L, Rowbottom L, McDonald R, Bjarnason GA, Tsao M, Barnes E, Danjoux C, Popovic M, Lam H, et al. 2017. Effects of circadian rhythms and treatment times on the response of radiotherapy for painful bone metastases. Ann Palliat Med. 6(1):14–25. doi:10.21037/apm.2016.09.07.
   PubMed Web of Science ®Google Scholar
• Squire T, Buchanan G, Rangiah D, Davis I, Yip D, Chua YJ, Rich T, Elsaleh H. 2017. Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer? Chronobiol Int. 34(4):492–503. doi:10.1080/07420528.2017.1301462.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, et al. 2012. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol. 23(12):3110–3116. doi:10.1093/annonc/mds148.
   PubMed Web of Science ®Google Scholar
• Guo P, Wang H, Jiang R, Wang Z. The clinical effect study on malignant tumors with chronoradiotherapy. Biol Rhythm Res. 2015;46(2):249–255. doi:10.1080/09291016.2014.985001.
   Web of Science ®Google Scholar
• Griniatsos J, Michail OP, Theocharis S, Arvelakis A, Papaconstantinou I, Felekouras E, Pikoulis E, Karavokyros I, Bakoyiannis C, Marinos G, et al. 2006. Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa. World J Gastroenterol. 12(13):2109–2114. doi:10.3748/wjg.v12.i13.2109.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan RC, Sothern RB. 1999. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol. 154(2):613–622. doi:10.1016/S0002-9440(10)65306-0.
   PubMed Web of Science ®Google Scholar
• Buchi KN, Moore JG, Hrushesky WJ, Sothern RB, Rubin NH. 1991. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 101(2):410–415. doi:10.1016/0016-5085(91)90019-h.
   PubMed Web of Science ®Google Scholar
• Brown WR. 1991. A review and mathematical analysis of circadian rhythms in cell proliferation in mouse, rat, and human epidermis. J Invest Dermatol. 97(2):273–280. doi:10.1111/1523-1747.ep12480379.
   PubMed Web of Science ®Google Scholar
• Sothern RB, Smaaland R, Moore JG. 1995. Circannual rhythm in DNA synthesis (S-phase) in healthy human bone marrow and rectal mucosa. FASEB J. 9(5):397–403. doi:10.1096/fasebj.9.5.7896010.
   PubMed Web of Science ®Google Scholar
• Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG, Kleeberger SR, Bell DA. 2007. Identification of polymorphic antioxidant response elements in the human genome [published correction appears in Hum Mol Genet. 2007 Nov 15;16(22):2780]. Hum Mol Genet. 16(10):1188–1200. doi:10.1093/hmg/ddm066.
   PubMed Web of Science ®Google Scholar
• Kim JH, Thimmulappa RK, Kumar V, Cui W, Kumar S, Kombairaju P, Zhang H, Margolick J, Matsui W, Macvittie T, et al. 2014. NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest. 124(2):730–741. doi:10.1172/JCI70812.
   PubMed Web of Science ®Google Scholar
• Wible RS, Ramanathan C, Sutter CH, Olesen KM, Kensler TW, Liu AC, Sutter TR. 2018. NRF2 regulates core and stabilizing circadian clock loops, coupling redox and timekeeping in Mus musculus. Elife. 7:e31656. doi:10.7554/eLife.31656.
   PubMed Web of Science ®Google Scholar
• Xu YQ, Zhang D, Jin T, Cai DJ, Wu Q, Lu Y, Liu J, Klaassen CD. 2012. Diurnal variation of hepatic antioxidant gene expression in mice. PLoS One. 7(8):e44237. doi:10.1371/journal.pone.0044237.
   PubMed Web of Science ®Google Scholar
• Pekovic-Vaughan V, Gibbs J, Yoshitane H, Yang N, Pathiranage D, Guo B, Sagami A, Taguchi K, Bechtold D, Loudon A, et al. 2014. The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes Dev. 28(6):548–560. doi:10.1101/gad.237081.113.
   PubMed Web of Science ®Google Scholar
• Skrzypińska-Gawrysiak M, Piotrowski JK, Sporny S. Circadian variations in hepatotoxicity of carbon tetrachloride in mice. Int J Occup Med Environ Health. 2000;13(2):165–173.
   PubMedGoogle Scholar
• Bruckner JV, Ramanathan R, Lee KM, Muralidhara S. 2002. Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther. 300(1):273–281. doi:10.1124/jpet.300.1.273.
   PubMed Web of Science ®Google Scholar
• Manzella N, Bracci M, Strafella E, Staffolani S, Ciarapica V, Copertaro A, Rapisarda V, Ledda C, Amati M, Valentino M, et al. Circadian modulation of 8-Oxoguanine DNA Damage Repair. Sci Rep. 2015;5(1):13752. Published 2015 Sep 4. doi:10.1038/srep13752.
   PubMedGoogle Scholar
• Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. 2010. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A. 107(11):4890–4895. doi:10.1073/pnas.0915085107.
   PubMed Web of Science ®Google Scholar
• Zhao Y, and Chen Q. Diurnal variations in immunity. In eLS, John Wiley & Sons, Ltd (Ed.). https://doi.org/10.1002/9780470015902.a0028361.
   Google Scholar
• Feigin RD, Middelkamp JN, Reed C. 1972. Circadian rhythmicity in susceptibility of mice to sublethal Coxsackie B3 infection. Nat New Biol. 240(97):57–58. doi:10.1038/newbio240057a0.
   PubMedGoogle Scholar
• Feigin RD, San Joaquin VH, Haymond MW, Wyatt RG. 1969. Daily periodicity of susceptibility of mice to pneumococcal infection. Nature. 224(5217):379–380. doi:10.1038/224379a0.
   PubMed Web of Science ®Google Scholar
• Shackelford PG, Feigin RD. 1973. Periodicity of susceptibility to pneumococcal infection: influence of light and adrenocortical secretions. Science. 182(4109):285–287. doi:10.1126/science.182.4109.285.
   PubMed Web of Science ®Google Scholar
• Ruben MD, Smith DF, FitzGerald GA, Hogenesch JB. 2019. Dosing time matters. Science. 365(6453):547–549. doi:10.1126/science.aax7621.
   PubMed Web of Science ®Google Scholar
• Scheving LE, Burns ER, Pauly JE, Tsai TH. 1978. Circadian variation in cell division of the mouse alimentary tract, bone marrow and corneal epithelium. Anat Rec. 191(4):479–486. doi:10.1002/ar.1091910407.
   PubMedGoogle Scholar